ATHE Company Profile and Key Details
Alterity Therapeutics Limited
ATHE Stock Price Chart
Stock Price Today
Alterity Therapeutics Limited (ATHE) stock declined over -9.62%, trading at $4.51 on NASDAQ, down from the previous close of $4.99. The stock opened at $5.10, fluctuating between $4.51 and $5.10 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
Company Information
| Employees | 10 |
| Beta | 0.68 |
| Sales or Revenue | $4.02M |
| 5Y Sales Change% | 3.276% |
| Fiscal Year Ends | June |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Alterity Therapeutics Limited (NASDAQ: ATHE) stock price is $4.51 in the last trading session. During the trading session, ATHE stock reached the peak price of $5.10 while $4.51 was the lowest point it dropped to. The percentage change in ATHE stock occurred in the recent session was -9.62% while the dollar amount for the price change in ATHE stock was -$0.48.
The NASDAQ listed ATHE is part of Biotechnology industry that operates in the broader Healthcare sector. Alterity Therapeutics Limited designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Rudolph Emile Tanzi Ph.D.
Chief Scientific Advisor and Member of R&D Advisory Board
Dr. Robert Cherny
Head of Research
Dr. Steven D. Targum
Chief Medical Advisor
Ms. Kathryn J. E. Andrews
Chief Financial Officer
Dr. David A. Stamler M.D.
Chief Executive Officer
Mr. Geoffrey Paul Kempler B.Sc, B.Sc.
Co-Founder & Non-Executive Chairman
Mr. Phillip Allen Hains BBus(Acc), CA, MBA
Chief Financial Officer & Company Sec.
Mr. Phillip Allen Hains BBus(Acc), C.A., CA, M.B.A., MBA
Chief Financial Officer & Company Sec.
ATHE's closing price is 351% higher than its 52-week low of $1.00 where as its distance from 52-week high of $5.87 is -23.17%.
Number of ATHE employees currently stands at 10.
Official Website of ATHE is: https://alteritytherapeutics.com
ATHE could be contacted at phone 613 934 94906 and can also be accessed through its website. ATHE operates from 460 Bourke Street, Melbourne, VIC 3000, Australia.
ATHE stock volume for the day was 122.15K shares. The average number of ATHE shares traded daily for last 3 months was 476.72K.
The market value of ATHE currently stands at $40.04M with its latest stock price at $4.51 and 8.88M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com